Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Oramed Pharmaceuticals Inc maintains a gross margin of 0.65%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -470.80%, while the net margin is 2700.35%. These profitability ratios, combined with a Return on Equity (ROE) of 24.38%, provide a clear picture of how effectively ORMP converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ORMP competes directly with industry leaders such as GNLX and STRO. With a market capitalization of $134.93M, it holds a leading position in the sector. When comparing efficiency, ORMP's gross margin of 0.65% stands against GNLX's N/A and STRO's 100.00%. Such benchmarking helps identify whether Oramed Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
